[QUOTE=jeffreyn;1238496]Todd Sherer (MJFF) gave an update on c-Abl related matters a couple of days ago. He writes about the upcoming MJFF el al. trial, and also about the work of Inhibikase, and the work of Georgetown University:

Uncovering the Promise of c-Abl as a Therapeutic Target: Testing Available Treatments and Supporting New Therapies | Parkinson's Disease

Something else which may be of interest is the MJFF grant record for the current phase (i.e. the planning phase) of the MJFF et al. nilotinib trial:


Thanks Jeffrey. The only update I would have on the above is that the MJFF et al trial is more likely to begin around Sept. Originally, the hope was mid-year (July). I also wouldn't be surprised if it pushes back a little more from there. But, it will happen, which is what matters.